Sema4 Stock Forecast, Price & News

Sema4 (NASDAQ:SMFR) Frequently Asked Questions

Is Sema4 a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sema4 in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sema4 stock.
View analyst ratings for Sema4 or view top-rated stocks.

When is Sema4's next earnings date?

Sema4 is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Sema4.

How were Sema4's earnings last quarter?

Sema4 Holdings Corp (NASDAQ:SMFR) released its quarterly earnings data on Monday, November, 15th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.34. The firm earned $43.18 million during the quarter, compared to the consensus estimate of $42 million.
View Sema4's earnings history.

What guidance has Sema4 issued on next quarter's earnings?

Sema4 updated its FY 2021 earnings guidance on Monday, December, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $201 million-$204 million, compared to the consensus revenue estimate of $200.99 million.

What price target have analysts set for SMFR?

4 equities research analysts have issued 1-year price targets for Sema4's shares. Their forecasts range from $12.00 to $13.00. On average, they expect Sema4's stock price to reach $12.50 in the next year. This suggests a possible upside of 209.4% from the stock's current price.
View analysts' price targets for Sema4 or view top-rated stocks among Wall Street analysts.

Who are some of Sema4's key competitors?

Some companies that are related to Sema4 include LifeStance Health Group (LFST), Privia Health Group (PRVA), U.S. Physical Therapy (USPH), Sharecare (SHCR), InnovAge (INNV), The Pennant Group (PNTG), UpHealth (UPH), CRH Medical (CRHM), Italk (TALK), P3 Health Partners (PIII), Better Therapeutics (BTTX), Covalon Technologies (CVALF), Pear Therapeutics (PEAR), Thimble Point Acquisition (THMA) and Union Dental (UDHI).
View all of SMFR's competitors.

What is Sema4's stock symbol?

Sema4 trades on the NASDAQ under the ticker symbol "SMFR."

How do I buy shares of Sema4?

Shares of SMFR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sema4's stock price today?

One share of SMFR stock can currently be purchased for approximately $4.04.

How much money does Sema4 make?

Sema4 has a market capitalization of $974.69 million.

How many employees does Sema4 have?

Sema4 employs 3 workers across the globe.

What is Sema4's official website?

The official website for Sema4 is cmlifesciencesspac.com.

Where are Sema4's headquarters?

Sema4 is headquartered at 667 Madison Avenue, New York NY, 10065.

How can I contact Sema4?

Sema4's mailing address is 667 Madison Avenue, New York NY, 10065. The company can be reached via phone at 800-298-6470 or via email at [email protected].